Comanaging Thyroid Eye Disease: Proactive Care Approaches (CE Monograph)

Activity Description and Purpose

Thyroid eye disease (TED) is a debilitating autoimmune condition, often associated with Graves disease, that is characterized by inflammation and tissue remodeling in the orbit. This activity will review the clinical features of TED and methods for assessing clinical activity using the clinical activity score; it will explore the overlap between TED and dry eye disease to identify patients who may benefit from referral to a specialist. A comprehensive review of current management options will also be provided, including the introduction of teprotumumab, the first and only US Food and Drug Administration–approved treatment for TED, to help clinicians learn how to select appropriate treatments across a spectrum of disease activity and duration and to apply best practices for multidisciplinary management. This activity is designed for all clinicians involved in the care of patients with TED. The desired results of this activity are for clinicians treating TED to improve their ability to successfully manage this disease across broad clinical scenarios.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review the possible clinical features and methods of clinical activity assessment in thyroid eye disease
  • Review the most recent clinical data for teprotumumab, the only approved treatment for thyroid eye disease
  • Describe relevant clinical data for current treatments for thyroid eye disease
  • Select appropriate treatments for patients with thyroid eye disease across a spectrum of disease activity and duration
  • Apply guidelines for multidisciplinary management of teprotumumab-associated adverse effects
  • Develop clinical care plans that facilitate the optometrist’s role in the comanagement of thyroid eye disease
Course summary
Available credit: 
  • 1.50 COPE
Course opens: 
02/14/2025
Course expires: 
02/28/2026

Faculty

Andrew G. Lee, MD (Chair)
Herb and Jean Lyman Centennial Chair in Ophthalmology
Department of Ophthalmology
Blanton Eye Institute
Professor of Ophthalmology, Neurology, and Neurosurgery
Academic Institute
Full Clinical Member
Research Institute
Houston Methodist
Weill Cornell Medical College
Houston, Texas
Kenneth A. Beckman, MD, FACS
Clinical Assistant Professor of Ophthalmology
Ohio State University
Columbus, Ohio
Director of Corneal Surgery
Comprehensive Eye Care of Central Ohio
Westerville, Ohio
Amina I. Malik, MD
Associate Professor of Clinical Ophthalmology
Academic Institute
Houston Methodist
Weill Cornell Medical College
Chief of Oculoplastic and Reconstructive Surgery
Houston Methodist Eye Associates
Houston, Texas

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity.

Faculty

Kenneth A. Beckman, MD, is a consultant for AbbVie Inc, Alcon, Amgen, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Dompé US, Inc, Glaukos Corporation, Invirsa Inc, Johnson & Johnson Vision Care, Inc*, Novartis Pharmaceuticals Corporation*, Ocular Science, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc*, Thea Pharma Inc, Trukera Medical, Verséa Health, Inc, Viatris Inc, Visus Therapeutics, and Yuyu Pharma, Inc; is a contracted researcher for Glaukos Corporation; and has stocks or stock options in RxSIGHT*.

Andrew G. Lee, MD, is a consultant for AstraZeneca and Bristol-Myers Squibb; is an advisory board member of Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Alexion Pharmaceuticals Inc and Amgen Inc.

Amina I. Malik, MD, is a consultant for Amgen Inc.

* The financial relationship existed during the past 24 months but has now ended

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 96148-SD (Asynchronous)
COPE Course Category: Systemic/Ocular Disease

Administrator: 

This activity, COPE Activity Number 130075, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by 

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at [email protected].

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Amgen Inc.

This CE activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 334

Available Credit

  • 1.50 COPE
Please login or register to take this course.

Clicking Take course indicates that you have reviewed the CE information for this activity.